John Serfas, MD
Interventional Cardiology · Kansas City, KSNPI 1508203761
Payments from drug & device makers
What this record shows
This record is dominated by grants: $26,433 of the $30,708 with a category attached, or 86.1%. Medtronic accounts for 68.8% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2021 at $23,835 and has fallen 98.4% since, to $392 in 2025.
Across 68 payments — averaging $451.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$21K
- Abbott$7K
- Edwards Lifesciences$1K
- Boston Scientific$169
- W. L. Gore & Associates, Inc.$165
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$149
- plus $906 from 18 others
What the payments were for
- Grants$26,43386%
- Travel & lodging$6452%
- Food & beverage$3,62912%
- Education$10%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 20 | $21,141 |
| Abbott | 4 | $7,098 |
| Edwards Lifesciences | 12 | $1,079 |
| Boston Scientific | 2 | $169 |
| W. L. Gore & Associates, Inc. | 1 | $165 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $149 |
| Cardiva Medical, Inc. | 1 | $126 |
| Philips North America LLC | 1 | $108 |
| GE HealthCare | 1 | $100 |
| B. Braun Interventional Systems Inc. | 1 | $87 |
| Penumbra, Inc. | 2 | $87 |
| Novo Nordisk | 3 | $80 |
| Pfizer | 3 | $50 |
| Cathworks, Inc. | 1 | $45 |
| Abiomed | 2 | $43 |
| E.r. Squibb & Sons, L.L.C. | 2 | $38 |
| Sanofi-aventis U.S. LLC | 1 | $28 |
| Amgen | 1 | $21 |
| Boehringer Ingelheim | 1 | $19 |
| Cook Medical LLC | 1 | $16 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $16 |
| AstraZeneca | 1 | $15 |
| Scpharmaceuticals Inc. | 1 | $15 |
| Cordis US CORP. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$30,708 in reported general payments places this provider in the 85th percentile of 55 interventional cardiology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 48 | $51,388 |
| EliquisApixaban | 25 | $26,809 |
| WegovySemaglutide | 13 | $19,908 |
| Metoprolol Succinate | 71 | $907 |
| Midodrine Hcl | 12 | $553 |
| Spironolactone | 53 | $498 |
| Atorvastatin Calcium | 36 | $484 |
| Warfarin Sodium | 27 | $349 |
| Losartan Potassium | 31 | $313 |
| Potassium Chloride | 16 | $231 |
| Ezetimibe | 12 | $136 |
| Furosemide | 20 | $118 |
| Amlodipine Besylate | 25 | $94 |
| Carvedilol | 22 | $93 |
| Torsemide | 11 | $81 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $19 | $51,38848 claims |
| PfizerEliquis | $50 | $26,80925 claims |
| Novo NordiskWegovy | $80 | $19,90813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 55 interventional cardiology providers in Kansas.
Other interventional cardiology in Kansas City
- Anthony SpaedyKansas City$385K
- Prasad GunasekaranKansas City$76K
- Kamal GuptaKansas City$46K
- Mark WileyKansas City$39K
- Venkat PasnooriKansas City$21K
- Peter TadrosKansas City$20K
- Eric HockstadKansas City$15K
- Georges HajjKansas City$5K
- Ashwani MehtaKansas City$4K
- Maheedhar GedelaWichita$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.